

RESULT 5
 AAN31706
 ID AAN31706 standard; protein; 1363 AA.
 XX
 AC AAN31706;
 XX
 DI 16-JUN-2007 (revised);
 DT 26-MAR-2003 (revised)
 DI 14-APR-1999 (first entry)
 XX
 DE Bovine coronavirus E2 (S) protein.
 XX
 KW BCV; E2 protein; peplomer protein; S spike; antigen; vaccine; ocular;
 KW BOND_PC; S peplomer polypeptide precursor;
 KW S peplomer polypeptide precursor [Bovine coronavirus];
 KW spike glycoprotein; spike glycoprotein [bovine coronavirus]; G05529;
 KW G06944; G05405; G016026; G016021; G019051; G019061; G019564; G046789;
 KW G046513.
 XX
 OS Bovine coronavirus.
 XX
 FH Key Location/Qualifiers
 FT Peptide 2..17
 FT /label= Sig_peptide
 FT Protein 18..1363
 FT /label= Mem_protein
 FT Domain 1306..1338
 FT /note= "transmembrane domain"
 XX
 FN US5672350-A.
 XX
 FD 30-SEP-1997.
 XX
 FF 22-DEC-1995; 93US-00171769.
 XX
 FR 22-AUG-1989; 89US-00397659.
 FR 18-OCT-1991; 91US-00779500.
 FR 19-DEC-1991; 91US-00821422.
 XX
 PA (VETE-) VETERINARY INFECTIOUS DISEASE.
 XX
 PT Sabiu LA, Parker MD, Cox GU;
 XX
 DE NFI: 1997-428523/45.
 DE N-PDB: AAT89387.
 DE EC:ECBI: g117529675.
 DE EC:SWISSPROT: E25193.
 XX
 FT Vaccines against bovine coronavirus - containing recombinant bovine
 FT coronavirus polypeptide(s).
 XX
 PS Claim 13; Fig 3; 52pp; English.
 XX
 CC This polypeptide comprises the E2 protein, also designated peplomer
 CC protein or S (Spike), of bovine coronavirus (BCV). It has a mol.wt. of
 CC 150 kDa exclusive of glycosylation and contains 21 potential N-linked
 CC glycosylation sites. The amino acid sequence was deduced from a clone E2
 CC cDNA (see AAT89387). The E2 gene in plasmid pT13E2 (E. coli JM105) is
 CC deposited as ATCC 86041. The BCV E3 gene (see AAT89388) is immediately 5'
 CC of the E2 gene on the viral genome and terminates 14 nucleotides upstream
 CC from the E2 initiation codon. The E2 and E3 genes have been cloned and
 CC can be used for the recombinant production of BCV polypeptides, using
 CC e.g. Spodoptera frugiperda Sf9 insect cells as host cells. Glycosylated
 CC and non-glycosylated recombinant E2 and E3 (see AAN31707) are useful as
 CC components of vaccines directed toward preventing BCV infection, or
 CC reducing the severity of BCV infection, in bovine populations. (Updated
 CC on 26-MAR-2003 to correct FF field.)

XX
 SQ Sequence 1363 AA:

Query Match		55.24;	Score 6965;	DB 2;	Length 1363;
Best Local Similarity		95.44;	Fred. No. 0;		
Matches 1360;		Conservative	28;	Mismatches	38; Indels 9; Gaps 0;
Qy	1	MFLLILLSLHNAFAVIGELKCTTVSINHWDTGAFSISTDVVDTVGLSTYVVLNGLVYVLYNI	60		
Db	1	MFLLILLSLHNAFAVIGELKCTTVSINHWDTGAFSISTDVVDTVGLSTYVVLNGLVYVLYNI	60		
Qy	61	TILLNGYVFTSGSYRNKMLKSTLLSLTMFKFFFLSDPFGVFAKQVHTVIRKGVYS	120		
Db	61	TILLNGYVFTSGSYRNKMLKSTLLSLTMFKFFFLSDPFGVFAKQVHTVIRKGVYS	120		
Qy	121	EFPAITISSTFWNISYSVYVQPTINELNKLGLLELLISVCGTTCDDPHTNCKPWLQWR	180		
Db	121	EFPAITISSTFWNISYSVYVQPTINELNKLGLLELLISVCGTTCDDPHTNCKPWLQWR	180		
Qy	181	VLNHWDTGVSCLYKRNHTVDNADLYFRFVQESSTFVAVFTDGVVTKFLINVYLS	240		
Db	181	VLNHWDTGVSCLYKRNHTVDNADLYFRFVQESSTFVAVFTDGVVTKFLINVYLS	240		
Qy	241	VLSHYVYVPLTCSANILEYVWVPLTFKQYLLAFNQGVDVFNAGVDCSDPNSKPKTLS	300		
Db	241	VLSHYVYVPLTCSANILEYVWVPLTFKQYLLAFNQGVDVFNAGVDCSDPNSKPKTLS	300		
Qy	301	LAPSTGVYELNGVTVQPIADVYRIHLEPCNIZANLCKSVSPPLWERTATSWCNPMK	360		
Db	301	LAPSTGVYELNGVTVQPIADVYRIHLEPCNIZANLCKSVSPPLWERTATSWCNPMK	360		
Qy	361	SLMSFTQADSEFTCHNIDAAKIYHMCFSSTIIDKFAIPNGKVDLQGLGVLSQPNYRI	420		
Db	361	SLMSFTQADSEFTCHNIDAAKIYHMCFSSTIIDKFAIPNGKVDLQGLGVLSQPNYRI	420		
Qy	421	DTATSCQLYMLFAANVSVSRFNSFNWRRFGTEQSVFQFQVGVFTHDVYVYQKCF	480		
Db	421	DTATSCQLYMLFAANVSVSRFNSFNWRRFGTEQSVFQFQVGVFTHDVYVYQKCF	480		
Qy	481	KAPNFCPCCKLQGLGVNGSPSIDAGYVNSIGTCSAGTHYLICYNMQCCLCTPDPPI	540		
Db	481	KAPNFCPCCKLQGLGVNGSPSIDAGYVNSIGTCSAGTHYLICYNMQCCLCTPDPPI	540		
Qy	541	SPSTGSPYKCFQKYLVGIGECGLAIKSDYCGGHPCTQQAFLGNSVDSCLQGRCHI	600		
Db	541	SPSTGSPYKCFQKYLVGIGECGLAIKSDYCGGHPCTQQAFLGNSVDSCLQGRCHI	600		
Qy	601	FANFILHVNSTTICSTDLQKSHDILLGVVNDLYISQGLFYEVNATYNSQKLL	660		
Db	601	FANFILHVNSTTICSTDLQKSHDILLGVVNDLYISQGLFYEVNATYNSQKLL	660		
Qy	661	YDSHGMVYGFREYINRITMIRACYSQVGRAGFNHNSSEFALLFRNKNVYVNTLSPQ	720		
Db	661	YDSHGMVYGFREYINRITMIRACYSQVGRAGFNHNSSEFALLFRNKNVYVNTLSPQ	720		
Qy	721	LQPINYFOSYLGCVVHADUSTSSVQCDLTVGSGVGVYSTERASRAITTSYRFINFE	780		
Db	721	LQPINYFOSYLGCVVHADUSTSSVQCDLTVGSGVGVYSTERASRAITTSYRFINFE	780		
Qy	781	FTTVNFMGSLFVGGLYEIQIPSEFTIGHMKEFIQTSFVKVTDGFFVVGQYVACKSSQ	840		
Db	781	FTTVNFMGSLFVGGLYEIQIPSEFTIGHMKEFIQTSFVKVTDGFFVVGQYVACKSSQ	840		
Qy	841	LVEYSSPCDMINAILTEVNELDITIQVANSIMNGVILSTKLKSGFVNVNVDINYSFVL	900		
Db	841	LVEYSSPCDMINAILTEVNELDITIQVANSIMNGVILSTKLKSGFVNVNVDINYSFVL	900		

Qy 901 GCLGSECHVSSRSRAIEDLLFSKVKLSVGVFVDYANCTGGAEIRDLICVQSYNGIKVLF 960
 D6 901 GCLGSECHVSSRSRAIEDLLFSKVKLSVGVFVEAYNCTGGAEIRDLICVQSYNGIKVLF 960

Qy 961 FLLEBNQISGYTLAATFASLFFPWSAAAGVPFYLNVQYRINGIGVIMDVLSQKQLISHA 1020
 D6 961 FLLEBNQISGYTLAATFASLFFPWSAAAGVPFYLNVQYRINGIGVIMDVLSQKQLISHA 1020

Qy 1021 FNNALDAIQEGFDATNSALVKIQAVVNANAEALNNLLQQLSNRFGAISASIQEILSRDLA 1080
 D6 1021 FNNALDAIQEGFDATNSALVKIQAVVNANAEALNNLLQQLSNRFGAISASIQEILSRDLA 1080

Qy 1081 LEAQAQIDRLINGRLTALNAVVSQQLSDSTLVKFSRAAQAMEKVNCECVKSQSSRINFQNG 1140
 D6 1081 LEAQAQIDRLINGRLTALNAVVSQQLSDSTLVKFSRAAQAMEKVNCECVKSQSSRINFQNG 1140

Qy 1141 NHIIISLVQNAFYGLYFIHFSYVPTFYVIKRVSPGLCIAGDPGIAFSSSTFVNVNINMT 1200
 D6 1141 NHIIISLVQNAFYGLYFIHFSYVPTFYVIKRVSPGLCIAGDPGIAFSSSTFVNVNINMT 1200

Qy 1201 GSGYYVPEFTIGNVVVVMTCAVNYIKAPDVMLNISTENLPDFKEELDQWEPNQTILMAD 1260
 D6 1201 GSGYYVPEFTIGNVVVVMTCAVNYIKAPDVMLNISTENLPDFKEELDQWEPNQTILMAD 1260

Qy 1261 LSLDYINVIFLDLQDENHRLQEAIKVLNHSYINLKDIGTYEYVYVNVVWLLIGLAGVA 1320
 D6 1261 LSLDYINVIFLDLQDENHRLQEAIKVLNHSYINLKDIGTYEYVYVNVVWLLIGLAGVA 1320

Qy 1321 MLVLLFFICCCCTGCGTSCFKICGGCCDDYTGHQELVINTSHDD 1363
 D6 1321 MLVLLFFICCCCTGCGTSCFKICGGCCDDYTGHQELVINTSHDD 1363